Pacira BioSciences Inc - Company Profile
Powered by 
All the sales intelligence you need on Pacira BioSciences Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Pacira BioSciences Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Pacira BioSciences Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Pacira BioSciences Inc (Pacira) is dedicated to addressing the pressing issue of pain management without relying on opioids. The company focuses on developing therapies that can be administered directly to the site of pain, thereby minimizing systemic side effects and enhancing patient outcomes.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Pacira's R&D arm focuses on developing innovative solutions for musculoskeletal pain and pain adjacencies. The company's R&D initiatives include the development of precise, targeted treatments that aim to transform pain management. The company is expanding its pipeline of locally administered, long-acting, opioid-sparing therapies and investing in breakthroughs such as gene therapy. PCRX-201, a gene therapy candidate for osteoarthritis of the knee, is a key focus, designed to reduce chronic inflammation by boosting cellular IL-1Ra production and blocking IL-1 pathway activation. The company's R&D unit is located in San Diego, California. This facility houses Science Center-related R&D activities, including formulation, analytical testing, clinical and process development activities for manufacturing additional commercial product indications and new pipeline products. It also includes a pilot plant suite for early-stage clinical product production. As of December 2025, the company had over 15 families of patents and patent applications related to the pMVL drug delivery technology and 29 families related to the technology used by iovera. There are two families of patents and patent applications relating to various aspects of the technology used by ZILRETTA. In FY2025, the company spent US$117.3 million on R&D, which as a percentage of revenue, stood at 16.1% and grew 43.8% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer